Orly International, Inc. – FDA 483, Dec 20, 2022
An FDA inspection of Orly International, Inc. in Van Nuys, CA, revealed significant deficiencies in the manufacturing and distribution of its OTC hand sanitizers and antifungal drug products. The firm failed to establish adequate stability data for product expiration dates, lacked a robust stability program, and did not validate its water system or manufacturing equipment. Additionally, issues were noted with cleaning validation, quality control unit responsibilities, and employee cGMP training, indicating a broad lack of adherence to good manufacturing practices.
ID · 39c9e563-689c-49d0-adf0-39074fd0bd1c
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.